JaLCDOI 10.18926/AMO/54607
フルテキストURL 70_5_425.pdf
著者 Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
抄録 Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
キーワード breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
発行日 2016-10
出版物タイトル Acta Medica Okayama
70巻
5号
出版者 Okayama University Medical School
開始ページ 425
終了ページ 427
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
Submission Path amo/vol70/iss5/18
PubMed ID 27777441
Web of Sience KeyUT 000388098700018
JaLCDOI 10.18926/AMO/53907
フルテキストURL 69_6_333.pdf
著者 Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
抄録 We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
キーワード breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type Original Article
発行日 2015-12
出版物タイトル Acta Medica Okayama
69巻
6号
出版者 Okayama University Medical School
開始ページ 333
終了ページ 338
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
Submission Path amo/vol69/iss6/2
PubMed ID 26690243
Web of Sience KeyUT 000368434500002
JaLCDOI 10.18926/AMO/53675
フルテキストURL 69_5_291.pdf
著者 Sugiu, Kumi| Iwamoto, Takayuki| Kelly, Catherine M.| Watanabe, Naoki| Motoki, Takayuki| Itoh, Mitsuya| Ohtani, Shoichiro| Higaki, Kenji| Imada, Takako| Yuasa, Takeshi| Omori, Masako| Sonobe, Hiroshi| Fujiwara, Toshiyoshi| Matsuoka, Junji|
抄録 Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
キーワード breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response
Amo Type Original Article
発行日 2015-10
出版物タイトル Acta Medica Okayama
69巻
5号
出版者 Okayama University Medical School
開始ページ 291
終了ページ 299
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
Submission Path amo/vol69/iss5/5
PubMed ID 26490026
Web of Sience KeyUT 000365519600005
著者 Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro|
発行日 2013-12-01
出版物タイトル BMC Cancer
13巻
資料タイプ 学術雑誌論文
著者 Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos|
発行日 2014-01
出版物タイトル Breast Cancer Research and Treatment
143巻
2号
資料タイプ 学術雑誌論文
タイトル(別表記) Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
フルテキストURL 126_25.pdf
著者 溝尾 妙子| 枝園 忠彦| 伊藤 麻衣子| 野上 智弘| 岩本 高行| 元木 崇之| 平 成人| 松岡 順治| 土井原 博義|
抄録  Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.  Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.  Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.  Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
キーワード OSNA法(OSNA method) センチネルリンパ節(sentinel lymph node) micrometastases CK-19
備考 原著 (Original Paper)
出版物タイトル 岡山医学会雑誌
発行日 2014-04-01
126巻
1号
出版者 岡山医学会
出版者(別表記) Okayama Medical Association
開始ページ 25
終了ページ 30
ISSN 0030-1558
NCID AN00032489
資料タイプ 学術雑誌論文
関連URL http://www.okayama-u.ac.jp/user/oma/
言語 Japanese
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
査読 有り
DOI 10.4044/joma.126.25
Sort Key 5
Eprints Journal Name joma
参考文献 1) Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM : Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer : overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol (2010) 11, 927-933. 2) Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Bussolati G, Boecker W, Borisch B, Connolly CE, Decker T, Dervan P, Drijkoningen M, et al. : Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer (2003) 39, 1654-1667. 3) Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, Ueda S, Mano M, Masuda N, Takeda M, Tsujimoto M, Yoshidome K, et al. : Molecular detection of lymph node metastases in breast cancer patients : results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res (2009) 15, 2879-2884. 4) Layfield DM, Agrawal A, Roche H, Cutress RI : Intraoperative assessment of sentinel lymph nodes in breast cancer. Br J Surg (2011) 98, 4-17. 5) Tamaki Y : One-step nucleic acid amplification assay (OSNA) for sentinel lymph node biopsy. Breast cancer (2012) [Epub ahcad of print]. 6) Osako T, Iwase T, Kimura K, Yamashita K, Horii R, Yanagisawa A, Akiyama F : Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer : a comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer (2011) 117, 4365-4374. 7) Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, Zurrida S, Maisonneuve P, Paganelli G, Mazzarol G : Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg (2005) 241, 319-325. 8) Rahusen FD, Torrenga H, van Diest PJ, Pijpers R, van der Wall E, Licht J, Meijer S : Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg (2001) 136, 1059-1063. 9) Travagli JP, Atallah D, Mathieu MC, Rochard F, Camatte S, Lumbroso J, Garbay JR, Rouzier R : Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients : predictors of non-sentinel lymph node metastasis. Eur J Surg Oncol (2003) 29, 403-406. 10) Cortesi L, Proietto M, Cirilli C, Tazzioli G, Andreotti A, Federico M : Prognosis and treatment of micrometastatic breast cancer sentinel lymph node : A population-based study. J Surg Oncol (2012) 106, 399-405. 11) Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M : Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis : a randomized clinical trial. JAMA (2011) 305, 569-575. 12) Glechner A, Wockel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, Kreienberg R : Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer : A systematic review and meta-analysis. Eur J Cancer (2013) 49, 812-825. 13) Cserni G : Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. J Clin Pathol (2012) 65, 193-199. 14) Snook KL, Layer GT, Jackson PA, de Vries CS, Shousha S, Sinnett HD, Nigar E, Singhal H, Chia Y, Cunnick G, Kissin MW : Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg (2011) 98, 527-535. 15) Vilardell F, Novell A, Martin J, Santacana M, Velasco A, Diez-Castro MJ, Cuevas D, Panades MJ, Gonzalez S, Llombart A,Iglesias E, Matias-Guiu X : Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA. Virchows Arch (2012) 460, 569-575. 16) Alvarenga CA, Paravidino PI, Alvarenga M, Dufloth R, Gomes M, Zeferino LC, Schmitt F : Expression of CK19 in invasive breast carcinomas of special histological types : implications for the use of one-step nucleic acid amplification. J Clin Pathol (2011) 64, 493-497. 17) Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, Kato Y, Tsuda H, Ueda S, Sato K : One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res (2007) 13, 4807-4816. 18) Schem C, Maass N, Bauerschlag DO, Carstensen MH, Loning T, Roder C, Batic O, Jonat W, Tiemann KC : One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients ; results of the German study group. Virchows Arch (2009) 454, 203-210.
著者 Nishikawa, Toshio| Takaoka, Munenori| Ohara, Toshiaki| Tomono, Yasuko| Hao, Huifang| Bao, Xiaohong| Fukazawa, Takuya| Wang, Zhigang| Sakurama, Kazufumi| Fujiwara, Yasuhiro| Motoki, Takayuki| Shirakawa, Yasuhiro| Yamatsuji, Tomoki| Tanaka, Noriaki| Fujiwara, Toshiyoshi| Naomoto, Yoshio|
発行日 2013-03
出版物タイトル Cancer Biology & Therapy
14巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/50407
フルテキストURL 67_3_145.pdf
著者 Ishihara, Setsuko| Taira, Naruto| Kawasaki, Kensuke| Ishibe, Youichi| Mizoo, Taeko| Nishiyama, Keiko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Komoike, Yoshifumi| Sato, Shuhei| Kanazawa, Susumu|
抄録 A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, -0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, -0.196;p value, 0.0143) and number of deliveries (parameter estimate, -0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s.
キーワード breast cancer mammographic breast density life style body mass index
Amo Type Original Article
発行日 2013-06
出版物タイトル Acta Medica Okayama
67巻
3号
出版者 Okayama University Medical School
開始ページ 145
終了ページ 151
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
Submission Path amo/vol67/iss3/3
PubMed ID 23804137
Web of Sience KeyUT 000320747900003
関連URL http://ousar.lib.okayama-u.ac.jp/metadata/50646
著者 今田 孝子| 松岡 順治| 元木 崇之| 岩本 高行| 大森 昌子| 伊波 茂道| 本後 登志江| 逸見 典子| 真壁 幹夫| 野上 浩實|
発行日 2012-12-03
出版物タイトル 岡山医学会雑誌
124巻
3号
資料タイプ 学術雑誌論文
著者 渡辺 信之| 髙岡 宗徳| 櫻間 一史| 友野 靖子| 畠山 慎二| 大森 修| 元木 崇之| 白川 靖博| 山辻 知樹| 羽井佐 実| 松岡 順治| Beer, David G.| 長塚 仁| 田中 紀章| 猶本 良夫|
発行日 2010-04-01
出版物タイトル 岡山医学会雑誌
122巻
1号
資料タイプ 学術雑誌論文
著者 松岡 順治| 田渕 陽子| 伊藤 充矢| 小野 亮子| 今田 孝子| 松川 啓義| 元木 崇之| 猶本 良夫| 金澤 右|
発行日 2006-09-01
出版物タイトル 岡山医学会雑誌
118巻
2号
資料タイプ 学術雑誌論文
著者 松岡 順治| 田渕 陽子| 小野 亮子| 今田 孝子| 梅岡 達生| 渡辺 直樹| 元木 崇之| 松川 啓義| 猶本 良夫| 田中 紀章| 柳井 広之| 大森 昌子|
発行日 2006-09-01
出版物タイトル 岡山医学会雑誌
118巻
2号
資料タイプ 学術雑誌論文
著者 松岡 順治| 田渕 陽子| 伊藤 充矢| 小野 亮子| 今田 孝子| 元木 崇之| 松川 啓義| 大森 昌子| 柳井 広之| 猶本 良夫| 田中 紀章|
発行日 2006-09-01
出版物タイトル 岡山医学会雑誌
118巻
2号
資料タイプ 学術雑誌論文